KaydedilenlerDerginizi ekleyin

Dergiler / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 2

Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration

Mustafa DOĞAN
Saadet GÜLTEKİN IRGAT
Safiye YİĞİT DIVARCI
Fatih ÖZÇURA
Sayfa
212–222
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

New treatments under development in the search for the ideal agent for AMD treatment will also be discussed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Age-related macular degeneration (AMD), which can result in central vision loss, is among the leading causes of blindness world wide.
📊
Temel Bulgular & Veri:This review focuses on important clinical studies using 3 anti-VEGF agents and their link with real-world evidence including data point specific to our country.
💡
Sonuç & Katkı:New treatments under development in the search for the ideal agent for AMD treatment will also be discussed.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Age-related macular degeneration (AMD), which can result in central vision loss, is among the leading causes of blindness world wide. The beginning of the anti-vascular endothelial growth factor (anti-VEGF) era has revolutionized the treatment of AMD. The efficacy of anti-VEGFs (bevacizumab, ranibizumab and aflibercept) has been proven in important clinical studies such as ANCHOR, MARINA and VIEW, leading to the widespread use of these agents in the treatment of AMD. This review focuses on important clinical studies using 3 anti-VEGF agents and their link with real-world evidence including data point specific to our country. Also, the efficacy of anti-VEGF agents and real-life treatment regimens will be reviewed. New treatments under development in the search for the ideal agent for AMD treatment will also be discussed.

🔖

Bu Makaleye Atıf Yap

DOĞAN, M., IRGAT, S. G., DIVARCI, S. Y., ÖZÇURA, F. (2022). Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. Retina-Vitreus, Cilt: 30 - Sayı: 2, 212–222. https://ajindex.com/articles/589055

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. WHO. Causes of blindness and visual impairment. Available [Online] at: http://www.who.int/blindness/causes/en/ Accessed on 4 October 2018
  2. Stewart MW. Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit. Mayo Clin Proc. 2012;87:77-88
  3. Vingerling JR, Dielemans I, Hoffmann A at al. The prevalence of age-related maculopathy in the Rotterdam study. Ophtalmology. 1995;12:205-10 4. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health.2014;2:106-16
  4. McLeod DS, Taomoto M, Otsuji T, et al. Quantifying changes in RPE and choroidal vasculature in eyes with agerelated maculardegeneration. Invest Ophthalmol Vis Sci. 2002; 43: 1986-93
  5. Gaengel K, Genove G, Armulik A, et al. Endothelial-mural cellsignaling in vascular development and angiogenesis. Arterioscler Thromb VascBiol. 2009; 29: 630-8
  6. Miao H, Tao Y, Li XX. In flammatory cytokines in aqueous humor of patientswith choroidal neovascularization. Mol Vis. 2012; 18: 574-80
  7. Martin DF, Maguire MG, Ying GS, et al; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908
  8. Heier JS, Brown DM, Chong V, et al. Intravitreal a flibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48
  9. Wykoff CC, Croft DE, Brown DM, et al; TREX-YBMD Study Group. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-YBMD 1-Year Results. Ophthalmology. 2015;122:2514-22
  10. Rofagha S, Bhisitkul RB, Boyer DS, et al; SEVENUP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-9 12. Presta LG, Chen H, O’Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9
  11. Gragoudas ES, Adamis AP, Cunningham Jr. ET, et al: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16 14. Brown DM, Michels M, Kaiser PK,. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116: 57-65, e55
  12. Rosenfeld PJ,